Dr. Bradley Alan Switzer, MD

Dr. Switzer practices at Reliant Medical Group - Worcester - Neponset Street in Worcester, Massachusetts.

Dr. Switzer's NPI, 1184779969, was assigned on January 24, 2007. Dr. Switzer holds Massachusetts license 233914.

Dr. Switzer's primary practice is Reliant Medical Group - Worcester - Neponset Street, at 5 Neponset Street, Worcester, MA 01606. The practice phone is (508) 853-2716.

Dr. Switzer's primary practice is Reliant Medical Group - Worcester - Neponset Street in Worcester, Massachusetts. Dr. Switzer is also affiliated with UMass Memorial Medical Center - University Campus. The medical group on file is Atrius Health. Dmand AI also links Dr. Switzer to 2 more hospitals and 1 medical group, each named with a free account. Dr. Switzer's employer is on file too: a breast imaging center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Switzer practices, 4 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Switzer's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Switzer is licensed in Massachusetts.

CMS data shows 23,791 Medicare services from Dr. Switzer across 29 procedure codes in 2024, for 453 Medicare patients. Medicare paid $132,972 for them.

CMS counts 453 Medicare patients who saw Dr. Switzer in 2024. The largest group is 65 to 74, with 193 patients. 75% of them have high cholesterol, and 74% have high blood pressure. 22% are also on Medicaid. Their average risk score is 2.36, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Switzer's median patient age at 67, with 65% women.

In 2024, Dr. Switzer wrote 1,362 Medicare Part D claims for 259 patients. 80% of them were for generic drugs. CMS names the drug for 1,047 of them, across 32 drugs with 11 or more claims each, at $2,201,140 in total drug cost. In 2023, CMS named 1,392 claims across 40 drugs.

Dr. Switzer accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Switzer as offering telehealth.

Dmand AI links Dr. Switzer to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Breast Neoplasms, Neoplasm Metastasis and Breast Diseases. Eli Lilly and Company sponsors the most, 2. Open Payments lists research payments to Dr. Switzer that name 2 trials.

CMS Open Payments shows 202 general payments to Dr. Switzer from 29 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 97% of the total. Bristol-Myers Squibb Company paid the most, $650. It also lists 4 research payments totaling $25,040 from 2019 to 2023, naming 2 clinical trials.